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Background
The inflammasome is a novel protein complex that stimu-
lates caspase-1 activation to promote the processing and
secretion of IL-1b, a pro-inflammatory cytokine, which is
among the most biologically important inflammatory
mediators in allergic airway diseases. Among the various
types of inflammasomes, Cryopyrin/NALP3 has been sug-
gested to be involved in sensing sterile stress response,
extracellular ATP, danger-associated molecular patterns
(DAMPs), and crystals. Recently inappropriate NALP3
inflammasome activity has been reported in various aller-
gic airway diseases including asthma. Therefore, inhibitors
of the NALP3 inflammasome offer considerable therapeu-
tic promise. Recently Omega-3 fatty acid derivates termed
resolvins have shown to alter the effects of pro-inflamma-
tory cytokine storm seen in inflammatory diseases. How-
ever the ability of resolvins to modulate the effects of
inflammasome activation has not been studied. We inves-
tigated whether resolvin treatment inhibits inflammasome
activation and regulates the functional effects of inflamma-
some mediated by IL-1b secretion.
Methods
In our study the inflammasome was activated by ATP
and H2O2 (known nflammasome activators in acute lung
injury) in the absence or presence of D series resolvins,
resolvin D1 and resolvin D2. Inflammasome activation
was assessed by analyzing IL-1b release (end product of
inflammasome activation) and caspase-1 cleavage (indica-
tor of inflammasome activation) in THP-1 cells. Further
inflammasome was activated in the presence or absence
of resolvin in THP-1 cells, and supernatants from these
cells were added to A549 cells and human primary small
airway epithelial cells (HPSAEC) to study inflammasome
mediated functional effects.
Results
Our results indicate that resolvin treatment ameliorates
inflammasome activation as indicated by decreased cas-
pase-1 activity and IL-1b release. In addition resolvin
treatment inhibits inflammasome mediated epithelial
cell activation as indicated by suppressed IL-8 release
and decreased and ICAM expression.
Conclusions
These novel findings suggest that resolvins can be used
to modulate the inflammasome activity as well as blunt
the effects of the IL-1b mediated cytokine storm stem-
ming from inflammasome activation. These results may
offer a therapeutic approach to airway diseases such as
asthma, where ungoverned pro-inflammatory cytokine
secretion exacerbates the disease pathology.
Published: 23 April 2013
doi:10.1186/1939-4551-6-S1-P77
Cite this article as: Ruan and Kolliputi: Mechanisims of asthma and
allergic disease – 1081. Resolvin inhibits the cryopyrin/nalp3
inflammasome. World Allergy Organization Journal 2013 6(Suppl 1):P77.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color figure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Internal Medicine, University of South Florida, Tampa, USA
Ruan and Kolliputi World Allergy Organization Journal 2013, 6(Suppl 1):P77
http://www.waojournal.org/content/6/S1/P77
© 2013 Ruan; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.
